Arrowhead Net Debt vs Short Term Debt Analysis

ARWR Stock

USD 22.08 2.64 10.68%

Arrowhead Pharmaceuticals financial indicator trend analysis is way more than just evaluating Arrowhead Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arrowhead Pharmaceuticals is a good investment. Please check the relationship between Arrowhead Pharmaceuticals Net Debt and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Net Debt vs Short Term Debt

Net Debt vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arrowhead Pharmaceuticals Net Debt account and Short Term Debt. At this time, the significance of the direction appears to have no relationship.

The correlation between Arrowhead Pharmaceuticals' Net Debt and Short Term Debt is 0.04. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Arrowhead Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Arrowhead Pharmaceuticals' Net Debt and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Arrowhead Pharmaceuticals are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Net Debt i.e., Arrowhead Pharmaceuticals' Net Debt and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Short Term Debt

Most indicators from Arrowhead Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 05/12/2024, Enterprise Value is likely to grow to about 3.3 B, while Selling General Administrative is likely to drop slightly above 79.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	243.2M	228.2M	262.5M	275.6M
Total Revenue	243.2M	240.7M	276.8M	290.7M

Gross Profit Total Revenue

Arrowhead Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		0.9	-0.68	0.26	0.78	0.87	0.04	-0.92	0.79	0.66	0.93	0.76	0.54	0.24	0.76	0.87	-0.72	0.67	0.95	0.92	0.85	0.53	0.74	0.26	0.36	0.88
Short Long Term Debt Total	0.9		-0.92	-0.12	0.5	0.99	0.38	-0.88	0.9	0.38	0.97	0.93	0.17	-0.1	0.63	0.72	-0.91	0.7	0.88	0.95	0.97	0.15	0.83	0.24	0.02	0.97
Other Current Liab	-0.68	-0.92		0.42	-0.28	-0.94	-0.52	0.7	-0.91	-0.16	-0.87	-0.97	0.18	0.36	-0.42	-0.5	0.87	-0.5	-0.71	-0.77	-0.94	0.2	-0.84	-0.02	0.28	-0.85
Total Current Liabilities	0.26	-0.12	0.42		0.42	-0.2	-0.72	-0.14	-0.24	0.63	-0.06	-0.35	0.82	0.78	0.26	0.33	0.26	0.16	0.13	0.13	-0.22	0.83	0.01	0.28	0.98	-0.05
Total Stockholder Equity	0.78	0.5	-0.28	0.42		0.49	-0.4	-0.63	0.54	0.8	0.63	0.43	0.64	0.37	0.7	0.78	-0.17	0.17	0.8	0.48	0.52	0.64	0.51	-0.14	0.39	0.41
Property Plant And Equipment Net	0.87	0.99	-0.94	-0.2	0.49		0.42	-0.86	0.94	0.33	0.98	0.97	0.07	-0.12	0.61	0.7	-0.89	0.62	0.88	0.91	0.99	0.06	0.82	0.13	-0.07	0.95
Net Debt	0.04	0.38	-0.52	-0.72	-0.4	0.42		-0.17	0.32	-0.71	0.31	0.46	-0.61	-0.38	-0.17	-0.16	-0.56	0.26	0.06	0.29	0.41	-0.62	0.04	0.12	-0.62	0.42
Retained Earnings	-0.92	-0.88	0.7	-0.14	-0.63	-0.86	-0.17		-0.78	-0.51	-0.89	-0.76	-0.42	-0.09	-0.83	-0.91	0.78	-0.7	-0.94	-0.9	-0.84	-0.41	-0.69	-0.3	-0.23	-0.88
Accounts Payable	0.79	0.9	-0.91	-0.24	0.54	0.94	0.32	-0.78		0.36	0.94	0.97	-0.05	-0.14	0.6	0.66	-0.73	0.39	0.86	0.76	0.97	-0.06	0.84	-0.16	-0.17	0.81
Cash	0.66	0.38	-0.16	0.63	0.8	0.33	-0.71	-0.51	0.36		0.43	0.24	0.75	0.33	0.65	0.71	-0.13	0.27	0.62	0.44	0.33	0.76	0.56	0.06	0.63	0.32
Non Current Assets Total	0.93	0.97	-0.87	-0.06	0.63	0.98	0.31	-0.89	0.94	0.43		0.94	0.2	0.04	0.66	0.76	-0.82	0.58	0.93	0.92	0.98	0.19	0.81	0.09	0.05	0.93
Non Currrent Assets Other	0.76	0.93	-0.97	-0.35	0.43	0.97	0.46	-0.76	0.97	0.24	0.94		-0.13	-0.21	0.52	0.59	-0.81	0.43	0.81	0.79	0.99	-0.14	0.83	-0.09	-0.25	0.85
Cash And Short Term Investments	0.54	0.17	0.18	0.82	0.64	0.07	-0.61	-0.42	-0.05	0.75	0.2	-0.13		0.53	0.51	0.59	-0.06	0.46	0.4	0.38	0.02	1.0	0.11	0.51	0.84	0.23
Net Receivables	0.24	-0.1	0.36	0.78	0.37	-0.12	-0.38	-0.09	-0.14	0.33	0.04	-0.21	0.53		0.12	0.14	0.25	-0.04	0.13	0.12	-0.1	0.55	-0.14	0.03	0.74	-0.02
Common Stock Total Equity	0.76	0.63	-0.42	0.26	0.7	0.61	-0.17	-0.83	0.6	0.65	0.66	0.52	0.51	0.12		0.93	-0.45	0.49	0.85	0.64	0.6	0.51	0.55	0.16	0.28	0.6
Common Stock Shares Outstanding	0.87	0.72	-0.5	0.33	0.78	0.7	-0.16	-0.91	0.66	0.71	0.76	0.59	0.59	0.14	0.93		-0.52	0.57	0.92	0.75	0.68	0.59	0.66	0.21	0.38	0.69
Inventory	-0.72	-0.91	0.87	0.26	-0.17	-0.89	-0.56	0.78	-0.73	-0.13	-0.82	-0.81	-0.06	0.25	-0.45	-0.52		-0.82	-0.66	-0.9	-0.84	-0.04	-0.64	-0.47	0.09	-0.95
Other Current Assets	0.67	0.7	-0.5	0.16	0.17	0.62	0.26	-0.7	0.39	0.27	0.58	0.43	0.46	-0.04	0.49	0.57	-0.82		0.53	0.84	0.52	0.44	0.41	0.84	0.32	0.81
Other Stockholder Equity	0.95	0.88	-0.71	0.13	0.8	0.88	0.06	-0.94	0.86	0.62	0.93	0.81	0.4	0.13	0.85	0.92	-0.66	0.53		0.84	0.88	0.4	0.76	0.07	0.2	0.82
Total Liab	0.92	0.95	-0.77	0.13	0.48	0.91	0.29	-0.9	0.76	0.44	0.92	0.79	0.38	0.12	0.64	0.75	-0.9	0.84	0.84		0.86	0.37	0.72	0.46	0.27	0.98
Property Plant And Equipment Gross	0.85	0.97	-0.94	-0.22	0.52	0.99	0.41	-0.84	0.97	0.33	0.98	0.99	0.02	-0.1	0.6	0.68	-0.84	0.52	0.88	0.86		0.01	0.83	0.01	-0.11	0.91
Total Current Assets	0.53	0.15	0.2	0.83	0.64	0.06	-0.62	-0.41	-0.06	0.76	0.19	-0.14	1.0	0.55	0.51	0.59	-0.04	0.44	0.4	0.37	0.01		0.11	0.5	0.85	0.22
Short Term Debt	0.74	0.83	-0.84	0.01	0.51	0.82	0.04	-0.69	0.84	0.56	0.81	0.83	0.11	-0.14	0.55	0.66	-0.64	0.41	0.76	0.72	0.83	0.11		-0.05	0.12	0.72
Common Stock	0.26	0.24	-0.02	0.28	-0.14	0.13	0.12	-0.3	-0.16	0.06	0.09	-0.09	0.51	0.03	0.16	0.21	-0.47	0.84	0.07	0.46	0.01	0.5	-0.05		0.42	0.42
Current Deferred Revenue	0.36	0.02	0.28	0.98	0.39	-0.07	-0.62	-0.23	-0.17	0.63	0.05	-0.25	0.84	0.74	0.28	0.38	0.09	0.32	0.2	0.27	-0.11	0.85	0.12	0.42		0.1
Non Current Liabilities Total	0.88	0.97	-0.85	-0.05	0.41	0.95	0.42	-0.88	0.81	0.32	0.93	0.85	0.23	-0.02	0.6	0.69	-0.95	0.81	0.82	0.98	0.91	0.22	0.72	0.42	0.1

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Other Current Liab	13.5M	23.8M	(5.6M)	(46.4M)	(53.4M)	(50.7M)
Total Current Liabilities	40.7M	146.5M	74.1M	866K	995.9K	946.1K
Total Stockholder Equity	461.8M	408.8M	106.0M	271.3M	312.0M	327.6M
Property Plant And Equipment Net	47.0M	66.0M	168.6M	335.6M	385.9M	405.2M
Net Debt	(122.4M)	(158.9M)	(26.4M)	4.3M	3.9M	4.0M
Retained Earnings	(503.8M)	(644.7M)	(820.8M)	(1.0B)	(923.4M)	(877.3M)
Accounts Payable	6.8M	9.5M	2.9M	35.9M	41.2M	43.3M
Cash	143.6M	184.4M	108.0M	110.9M	127.5M	133.9M
Non Current Assets Total	200.1M	325.6M	315.5M	654.7M	752.9M	790.5M
Non Currrent Assets Other	265.4K	272K	29.1M	361.9M	416.2M	437.0M
Cash And Short Term Investments	315.5M	367.8M	376.4M	110.9M	127.5M	83.7M
Net Receivables	327.4K	661.4K	845.7K	10.3M	1.4M	0.0
Common Stock Total Equity	187.9K	194.7K	197K	198K	227.7K	239.1K
Common Stock Shares Outstanding	100.7M	103.7M	105.4M	106.8M	122.8M	128.9M
Liabilities And Stockholders Equity	522.5M	710.1M	691.9M	765.6M	880.4M	924.4M
Inventory	3.3M	4.3M	4.4M	(21.6M)	(19.5M)	(18.5M)
Other Current Assets	1.8M	2.2M	20.2M	7.1M	8.1M	8.6M
Other Stockholder Equity	965.4M	1.1B	820.9M	1.3B	1.5B	1.6B
Total Liab	60.7M	301.3M	586.0M	478.4M	550.1M	577.7M
Property Plant And Equipment Gross	47.0M	88.9M	110.3M	377.5M	434.1M	455.8M
Total Current Assets	322.4M	384.6M	376.4M	110.9M	127.5M	85.9M
Accumulated Other Comprehensive Income	18.4K	(69K)	(136K)	(3.2M)	(2.9M)	(2.8M)
Short Term Debt	1.1M	2.3M	2.8M	10.6M	12.1M	12.8M
Common Stock	194.7K	197K	106.0M	200K	230K	218.5K
Current Deferred Revenue	19.3M	111.1M	74.1M	866K	995.9K	946.1K
Non Current Liabilities Total	20.0M	154.8M	511.9M	477.5M	549.2M	576.6M
Property Plant Equipment	30.9M	48.7M	110.3M	335.6M	385.9M	405.2M
Other Assets	68.9M	96.8M	218K	210K	241.5K	229.4K
Short Term Investments	171.9M	183.4M	268.4M	292.7M	336.6M	353.5M
Intangible Assets	15.4M	13.7M	12.0M	10.3M	11.8M	10.2M
Other Liab	8.7M	41.4M	190.3M	56.0M	64.3M	67.6M
Net Tangible Assets	446.4M	395.2M	398.5M	261.1M	300.2M	202.9M

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Arrowhead Stock

0.87

EGRX

Eagle Pharmaceuticals

Pair Corr

Moving against Arrowhead Stock

0.75	VRCA	Verrica Pharmaceuticals Earnings Call Tomorrow	Pair Corr
0.67	YCBD	cbdMD Inc Earnings Call Tomorrow	Pair Corr
0.53	ELYM	Eliem Therapeutics Earnings Call Tomorrow	Pair Corr
0.51	JANX	Janux Therapeutics Financial Report 14th of May 2024	Pair Corr

The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.

The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:

How To Invest In Arrowhead

Details

Is Arrowhead Stock a good investment?

Details

What is Arrowhead Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Arrowhead Stock analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	FinTech Suite Use AI to screen and filter profitable investment opportunities

Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.098

Earnings Share

(2.77)

Revenue Per Share

0.319

Quarterly Revenue Growth

(0.94)

Return On Assets

(0.32)

The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arrowhead Net Debt vs Short Term Debt Analysis

Net Debt vs Short Term Debt

Net Debt vs Short Term Debt Correlation Analysis

Correlation Coefficient

Net Debt

Short Term Debt

Arrowhead Pharmaceuticals fundamental ratios Correlations

Arrowhead Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arrowhead Pharmaceuticals fundamental ratios Accounts

Pair Trading with Arrowhead Pharmaceuticals

Moving together with Arrowhead Stock

Moving against Arrowhead Stock

Complementary Tools for Arrowhead Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Non Currrent Assets Other
Current Deferred Revenue	+ 0.98	Total Current Liabilities
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net

Non Currrent Assets Other	- 0.97	Other Current Liab
Non Current Liabilities Total	- 0.95	Inventory
Other Stockholder Equity	- 0.94	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Other Current Liab
Property Plant And Equipment Net	- 0.94	Other Current Liab
Other Current Liab	- 0.92	Short Long Term Debt Total